Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Breast 2Other hematologic neoplasm 1NET 1Genitourinary 1Endocrine 1CNS 1

Conditions

Pheochromocytoma 2Neuroblastoma 2Pancreatic Neoplasms 1Neoplasm Metastasis 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoma, Islet Cell 1Adrenocortical Carcinoma 1

Interventions

Doxorubicin 4Sunitinib 3Radiosurgery 3Everolimus 3pembrolizumab 2exemestane 2Tamoxifen 2Specimen Handling 2Octreotide 2Magnetic Resonance Spectroscopy 2Fulvestrant 2Filgrastim 2Biopsy 2Bevacizumab 23-Iodobenzylguanidine 2tislelizumab 1surufatinib 1romidepsin 1regorafenib 1penpulimab 1pasireotide 1mercaptoundecahydrododecaborate 1lutetium Lu 177 dotatate 1lanreotide 1ganitumab 1folfirinox 1fludarabine phosphate 1epothilone B 1entrectinib 1dostarlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Granulocyte Colony-Stimulating Factor × Endocrine × Clear all
NCT03042780 2020-11-27

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
2 enrolled 6 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡